NBB ... I don't recall hearing anything about break-through possibilities until after Nov 13. So yeah, maybe/hopefully that strategy and possibility was born of the FDA review meeting. I would "think" RVX would have already made those applications, or is in the process of making them asap for obvious urgent business needs plus the impact those filings could/would have on pps as well as other business discussions & negotiations, if successful. Heres hoping the filing is underway for review, and for the best.

Ideally, it would be awesome to get at least narrow and specific indications through a break-through with further P4 studies or additional P3's for further indications, per some of the other posters' thought. 

Hopeful, but don't even know if anything has been filed, let alone the odds of success haha